Our faculty research in diverse subjects: psychosomatic issues, pain management, patient reporting and compliance behaviors, whole community and family roles in psychiatric conditions and treatment, teaching strategies and much more.
Steven Dubovsky, MD
Randomized, double-blind, parallel-group, placebo-controlled, dose ranging study of piromelatine in patients with mild dementia due to Alzheimer’s disease. Steven Dubovsky (Principal Investigator). Neurim Pharmaceuticals. $150,000. 1/1/2016-1/1/2018.
Access to Psychiatry Through Intermediate Care (APIC). Steven Dubovsky (Principal Investigator). Tower Foundation. $1,300,000. 1/1/2015-1/1/2017.
Open-label, long-term safety study of vilazodone in pediatric patients with major depressive disorder. Steven Dubovsky (Principal Investigator). Forest Research Institute. $221,000. 1/1/2015-1/1/2018.
Pain medication prescription following treatment for alcohol use disorder. Kenneth Leonard (Co-Principal Investigator), Edward Bednarczyk (Co-Investigator), Peter Elkin (Co-Principal Investigator), Walter Gibson (Co-Investigator), David Jacobs (Co-Investigator). National Institute on Alcoholism and Alcohol Abuse. $386,013. 7/1/2018-6/1/2019.
Expansion of MAT Practice in New York State. Kenneth Leonard (Principal Investigator), Brian Quigley (Co-Investigator). NYS OASAS. $750,000. 6/1/2017-5/1/2019.
In this custom-designed psychophysiology lab, our faculty, residents and fellows study the mechanisms by which the mind affects the body in psychosomatic illness by measuring heart rate and heart rate variability under lab stress conditions.